Novel Approaches For The Delivery Of Anti Hiv Drugs

HIV/AIDS continues to be one of the most challenging individual and public health concerns of the present day. According to the UNAIDS, nearly 38 million individuals were living with the infection by the end of 2018, while 1.7 million new cases occurred during that same year. In spite of the numerous advances in the development and delivery of antiretroviral agents, both for treatment and prevention, several challenges remain. This book includes original research and review articles on innovative strategies and approaches for the formulation and delivery of anti-HIV drugs, including genetic material and other biopharmaceuticals. Different local and systemic delivery strategies are addressed based on different technologies intended for oral, transdermal, subcutaneous, vaginal, or rectal administration. Authored by eminent scientists in academia and nonprofit organizations involved in the development of antiretroviral drug products, this collection provides useful information for all those involved in HIV/AIDS treatment and prevention.

HIV/AIDS continues to be one of the most challenging individual and public health concerns of the present day. According to the UNAIDS, nearly 38 million individuals were living with the infection by the end of 2018, while 1.7 million new cases occurred during that same year. In spite of the numerous advances in the development and delivery of antiretroviral agents, both for treatment and prevention, several challenges remain. This book includes original research and review articles on innovative strategies and approaches for the formulation and delivery of anti-HIV drugs, including genetic material and other biopharmaceuticals. Different local and systemic delivery strategies are addressed based on different technologies intended for oral, transdermal, subcutaneous, vaginal, or rectal administration. Authored by eminent scientists in academia and nonprofit organizations involved in the development of antiretroviral drug products, this collection provides useful information for all those involved in HIV/AIDS treatment and prevention.

These guidelines provide guidance on the diagnosis of human immunodeficiency virus (HIV) infection, the use of antiretroviral (ARV) drugs for treating and preventing HIV infection and the care of people living with HIV. They are structured along the continuum of HIV testing, prevention, treatment and care. This edition updates the 2013 consolidated guidelines on the use of antiretroviral drugs following an extensive review of evidence and consultations in mid-2015, shared at the end of 2015, and now published in full in 2016. It is being published in a changing global context for HIV and for health more broadly.

Infectious diseases are the leading cause of death globally, particularly among children and young adults. The spread of new pathogens and the threat of antimicrobial resistance pose particular challenges in combating these diseases. Major Infectious Diseases identifies feasible, cost-effective packages of interventions and strategies across delivery platforms to prevent and treat HIV/AIDS, other sexually transmitted infections, tuberculosis, malaria, adult febrile illness, viral hepatitis, and neglected tropical diseases. The volume emphasizes the need to effectively address emerging antimicrobial resistance, strengthen health systems, and increase access to care. The attainable goals are to reduce incidence, develop innovative approaches, and optimize existing tools in resource-constrained settings.

This volume summarizes recent advances in understanding the mechanisms of HIV-1 latency, in characterizing residual viral reservoirs, and in developing targeted interventions to reduce HIV-1 persistence during antiretroviral therapy. Specific chapters address the molecular mechanisms that govern and regulate HIV-1 transcription and latency; assays and technical approaches to quantify viral reservoirs in humans and animal models; the complex interchange between viral reservoirs and the host immune system; computational strategies to model viral reservoir dynamics; and the development of therapeutic approaches that target viral reservoir cells. With contributions from an interdisciplinary group of investigators that cover a broad spectrum of subjects, from molecular virology to proof-of-principle clinical trials, this book is a valuable resource for basic scientists, translational investigators, infectious-disease physicians, individuals living with HIV/AIDS and the general public.

During the past two decades, the world scientific community has witnessed major achievements in our understanding of the pathogenesis of HIV infection of the nervous system and HIV-Associated Dementia (HAD). Despite these giant gains, nervous system involvement during AIDS remains a relentlessly progressive disease with a deadly fate in many cases. This book on NeuroAIDS provides a unique resource for both general neurologists as well as basic neuroscientists with profound interests for research on NeuroAIDS. This book has special emphasis on the mechanisms of disease development and progression of HIV-infected patients with NeuroAIDS. The contributors have provided the readers with comprehensive reviews on clinical manifestations of HAD, mechanisms of HIV entry into the central nervous system, the role of cytokines and chemokines in pathogenesis of NeuroAIDS, drug abuse and NeuroAIDS, virus load in HAD, allostasis in HIV and AIDS, stroke in AIDS patients, and neuroimaging of HIV infection of the central nervous system. In addition, there are chapters on Varicella Zoster virus infection of HIV-seropositive and AIDS patients, as well as the molecular basis for opioids and AIDS virus interactions.

"These guidelines were produced by the World Health Organization (WHO), Department of Mental Health and Substance Abuse, in collaboration with the United Nations Office on Drugs and Crime (UNODC) a Guidelines Development Group of technical experts, and in consultation with the International Narcotics Control Board (INCB) secretariat and other WHO departments. WHO also wishes to acknowledge the financial contribution of UNODC and the Joint United Nations Programme on HIV/AIDS (UNAIDS) to this project. " - p. iv